Expesicor Overview
- Year Founded
-
2016
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Expesicor General Information
Description
Developer of therapeutics, imaging probes, and drug screening tools designed to prevent, treat, and cure neurological disorders. The company's novel positron emission tomography imaging agent assists in the visualization and objective measurement of pain, enabling healthcare providers to treat neurological maladies, including epilepsy, traumatic brain injury, and neurodegenerative disorders.
Contact Information
Website
www.expesicor.comCorporate Office
- 1121 East Broadway Street
- Missoula, MT 59802
- United States
Corporate Office
- 1121 East Broadway Street
- Missoula, MT 59802
- United States
Expesicor Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 09-May-2026 | Completed | Out of Business | |||
| 7. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 6. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 5. Seed Round | 01-Sep-2020 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 07-Nov-2019 | Completed | Startup | |||
| 3. Grant | 09-Sep-2019 | Completed | Startup | |||
| 2. Seed Round | 31-Jan-2019 | $1.1M | $1.1M | Completed | Startup | |
| 1. Grant | 25-Jul-2017 | $101K | Completed | Startup |
Expesicor Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed 2b | ||||||||
| Seed 2a | ||||||||
| Seed 1 | 494,382 | $0.000001 | $2.23 | $2.23 | 1x | $2.23 | 11.12% |
Expesicor Patents
Expesicor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017386526-A1 | A non-human animal model of neurodegenerative disorders | Active | 28-Dec-2016 | ||
| AU-2017386526-B2 | A non-human animal model of neurodegenerative disorders | Inactive | 28-Dec-2016 | ||
| CA-3048633-A1 | A non-human animal model of neurodegenerative disorders | Inactive | 28-Dec-2016 | ||
| EP-3562553-A1 | A non-human animal model of neurodegenerative disorders | Inactive | 28-Dec-2016 | ||
| EP-3562553-A4 | A non-human animal model of neurodegenerative disorders | Inactive | 28-Dec-2016 | A01K67/027 |
Expesicor Signals
Expesicor FAQs
-
When was Expesicor founded?
Expesicor was founded in 2016.
-
Where is Expesicor headquartered?
Expesicor is headquartered in Missoula, MT.
-
What is the size of Expesicor?
Expesicor has 3 total employees.
-
What industry is Expesicor in?
Expesicor’s primary industry is Drug Discovery.
-
Is Expesicor a private or public company?
Expesicor is a Private company.
-
What is Expesicor’s current revenue?
The current revenue for Expesicor is .
-
How much funding has Expesicor raised over time?
Expesicor has raised $3.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process